Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.92 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.92 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HLA-A | P04439 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxazosin SCHEMBL29359735 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL29429099 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL4725733 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL42621 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL158685 | 1.00 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL17652050 | 0.98 | KMT2A (0.95) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL10549641 | 0.97 | KMT2A (0.94) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL10416953 | 0.96 | KMT2A (0.93) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL1648487 | 0.96 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 | |
| Doxazosin SCHEMBL29711371 | 0.96 | KMT2A (1.00) | KMT2ACYP3A4HSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| US-20180125419-A1 | Methods and Compositions for Treating a Condition in a Subject | PALO ALTO INVESTORS | 2018-05-10 | — | — | US | disclosed |
| US-9833618-B2 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS (US) | 2017-12-05 | — | — | US | disclosed |
| US-9708509-B2 | Adhesives and related methods | AVERY DENNISON CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-9539216-B2 | Multi-phase, multi-compartment, capsular delivery apparatus and methods for using same | INNERCAP TECHNOLOGIES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3041677-A1 | CO-EXTRUDED MULTI-LAYER POLYESTER FILMS HAVING HYDROLYTIC STABILITY AND IMPROVED DELAMINATION RESISTANCE | Dupont Teijin Films U.S. Limited Partnership (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20140350041-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | PALO ALTO INVESTORS | 2014-11-27 | — | — | US | disclosed |
| US-20140212482-A1 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME | INNERCAP TECHNOLOGIES, INC. | 2014-07-31 | — | — | US | disclosed |
| US-7670612-B2 | Supplying active materials in various phases in single dosage multicompartment capsule | INNERCAP TECHNOLOGIES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070112327-A1 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS | 2007-05-17 | — | — | US | disclosed |
| US-20060206149-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-09-14 | — | — | US | disclosed |
| US-20060116721-A1 | Methods and compositions for treating a disease condition in a subject | PALO ALTO INVESTORS | 2006-06-01 | — | — | US | disclosed |
| WO-2006044694-A2 | METHODS AND COMPOSITIONS FOR TREATING A DISEASE CONDITION IN A SUBJECT | PALO ALTO INVESTORS (US) | 2006-04-27 | — | — | WO | disclosed |
| US-5663265-A | FREE RADICAL COPOLYMERIZATION FOR COATINGS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-02 | — | — | US | disclosed |
| US-5608012-A | SOLIDS, COATING SOLUTION PREPARED BY BULK POLYMERIZATION AND REACTION OF HYDROXY WITH ISOCYANATE | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| US-5596057-A | INTERPOLYMER FROM STERICALLY HINDERED UNSATURATED ESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |